Inspira TM Technologies Performed HYLA TM Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies The study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board

Technologies Performed HYLATM Blood Sensor

Study, in Preparation of Planned Human Studies

study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board

Israel, September 7, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or

"Inspira Technologies"), a groundbreaking respiratory support technology company, announces the completion of an animal study

that was conducted at Lahav C.R.O (contract research organization) by leading intensive care unit, or ICU, and respiratory specialists,

who are members of Inspira's Scientific Advisory Board. The completion of the animal study is an additional important step toward

initiating human studies using the HYLATM blood sensor.

an animal study, the HYLATM blood sensor performed measurements of blood parameters with results being compared to numerous

blood samples taken and analyzed using a routine blood gas analyzer, which is considered the standard of care used by hospitals today.

The HYLATM blood sensor is a non-invasive device, designed to provide continuous real-time measurements, overcoming the disadvantages

of standard blood gas analysis machines that require blood to be drawn and cannot provide a continuous display of data indicating the

patient's condition in real-time. These important characteristics of the HYLATM blood sensor may be vital in providing

immediate alerts of sudden changes in a patient's condition and may reduce risks, complications, and costs.

animal study was performed following prior successful ex-vivo data obtained with the HYLATM blood sensor in the Company's

laboratory. The lab results, accompanied by the encouraging animal study data, are important steps toward human studies.

Technologies OXY B.H.N. Ltd.

Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough

Augmented Respiration Technology (Inspira ART), designed to rebalance patient oxygen saturation levels. This technology potentially

allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation

systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and

has not been approved by any regulatory entity.

more information, please visit our corporate website:

Statement Disclaimer

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)